Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
by Zacks Equity Research
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
by Zacks Equity Research
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session.
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
by Zacks Equity Research
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
by Zacks Equity Research
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today
by Zacks Equity Research
Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab
by Zacks Equity Research
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $217.56 in the latest trading session, marking a +0.15% move from the prior day.
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $217.23 in the latest trading session, marking a -1.71% move from the prior day.
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
by Zacks Equity Research
Biogen Inc. (BIIB) concluded the recent trading session at $221.74, signifying a -0.98% move from its prior day's close.
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
by Zacks Equity Research
FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
Where Are Biotech ETFs Headed After Q4 Earnings?
by Yashwardhan Jain
Look into how Biotech ETFs performed after Q4 earnings.
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
by Zacks Equity Research
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.